Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Novo Nordisk (NVO) closed at $87.37, marking a -1.51% move from the previous day.
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk's recent CagriSema study disappointed and led to a massive selloff as investor pessimism deepened. Eli Lilly stock's relative outperformance could strengthen its bullish case, but NVO isn't expected to surrender market leadership just yet. NVO has several opportunities to expand indications on its weight loss drugs and potentially further its TAM.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over this period.
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company's potential following disappointing trial results for its CagriSema weight-loss drug.
Novo Nordisk's 27% drop was market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer's and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health's analysts said
US FDA approves Novo Nordisk's bleeding disorder drug
The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the agency said on Friday.
Novo Nordisk price target lowered to $105 from $155 at TD Cowen
TD Cowen lowered the firm's price target on Novo Nordisk to $105 from $155 and keeps a Buy rating on the shares.
BMO lowers Novo Nordisk price target to $105, says reaction to data 'overdone'
BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's Phase 3 data readout failed to meet investor expectations. CagriSema was supposed to best Eli Lilly's (LLY) Zepbound, but missed the mark on efficacy and tolerability, which "cuts the margin of error for execution in 2025," so Q4 results "cannot miss and the 2025 guide must be strong," the analyst tells investors. Given the data, the firm is cutting its Novo price target, but thinks the reaction in shares today has been "overdone," the analyst added. Novo Nordisk -17.25 (-16.67%) Eli Lilly +18.41 (+2.43%)
Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging
Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumbling as much as 24% at one point in premarket trading on Friday morning.
